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Abstract : Our group previously demonstrated the suppressive effect of glucagon-like 
peptide-1（GLP-1）on macrophage-driven atherosclerosis in apolipoprotein E-de-
cient （apoE-/-）mice.  In the present study we investigated the suppressive effect 
of GLP-1 on the atherogenic phenotype of vascular smooth muscle cells（VSMCs）
in vivo using apoE-/- mice, and the proliferation and migration of human VSMCs 
in vitro.  A 4-week infusion of GLP-1 in 17-week-old apoE-/- mice significantly 
reduced the proliferative VSMC phenotype stained with SMemb.  Platelet-derived 
growth factor（PDGF）-BB signicantly stimulated the proliferation of human aortic 
VSMCs by three fold.  Both 0.1 and 1 nmol / l GLP-1 signicantly suppressed the 
PDGF-induced VSMC proliferation, and this suppressive effect was significantly 
abolished by the GLP-1 receptor antagonist exendin（9−39）（50 nmol / l）.  The 
GLP-1 receptor agonists liraglutide（100 nmol / l）and exendin-4（100 nmol / l）mim-
icked GLP-1, signicantly suppressing PDGF-induced VSMC proliferation.  PDGF-
BB signicantly stimulated the migration of human aortic VSMCs by 1.7 -fold, and 
this effect was signicantly suppressed by 1 nmol / l GLP-1.  These ndings suggest 
that GLP-1-related treatments may prevent the progression of atherosclerotic lesions 
by suppressing the proliferation and migration of VSMCs, which are characteristic 
features of atherosclerosis.
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Introduction
　The incretins glucagon-like peptide-1 （GLP-1） and glucose-dependent insulinotropic polypeptide
（GIP） are secreted postprandially from the L-cells of the lower gut and the K-cells of the 
intestines, respectively, to regulate glucose homeostasis 1-3）.  GLP-1 and GLP-1 receptor （GLP-
1R） agonists, such as exendin-4 and liraglutide, have been reported to have cardioprotective 
and vasodilatory actions 4） and to improve vascular endothelial dysfunction and inflammation 5, 6）. 
Exendin-4 stimulates endothelial cell proliferation7） but suppresses monocyte adhesion to the 
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vascular wall and vascular smooth muscle cell （VSMC） proliferation 8, 9）.  Liraglutide stimulates 
nitric oxide production10） and attenuates tumor necrosis factor-α-induced oxidative stress and 
inflammation, as well as the expression of vascular cell adhesion molecule-1, intercellular 
adhesion molecule-1, and plasminogen activator inhibitor-1 in human umbilical vein endothelial 
cells 11, 12）.  Chronic infusion of GLP-1 suppresses monocyte / macrophage infiltration into the 
aortic wall and the development of atherosclerotic lesions in apolipoprotein E-deficient （apoE-/-） 
mice, an animal model of spontaneous atherosclerosis 13）.  GLP-1 works via GLP-1R to suppress 
oxidized low-density lipoprotein （oxLDL）-induced foam cell formation in exudate peritoneal 
macrophages, and this suppressive effect is followed by activation of cAMP 13）.
　In the present study we evaluated the degree to which GLP-1 inhibited the development of 
aortic atherosclerotic lesions as a result of reducing the area of atherosclerotic lesions infiltrated 
by proliferative VSMCs in apoE-/- mice.  We assessed the suppressive effects of GLP-1 and 
GLP-1R agonists on the proliferation and migration of human VSMCs, pivotal features of 
atherosclerosis.
Materials and methods
Chemicals and reagents
　Human GLP-1 （7−36） amide, exendin （9−39）, and exendin-4 were purchased from AnaSpec
（San Jose, CA, USA）.  Liraglutide was obtained from Bachem （Torrance, CA, USA）.  The 
dipeptidyl peptidase-4（DPP-4）inhibitor vildagliptin and its analog PKF275-055 were generous 
gifts of Novartis （Basel, Switzerland）.  Platelet-derived growth factor （PDGF）-BB was purchased 
from Wako （Osaka, Japan）.
Human VSMC proliferation assay
　Human aortic VSMCs were seeded on six-well plates （3×104 cells / ml per well） and cultured 
in smooth muscle cell basal medium （SmBM） supplemented with 5％ fetal calf serum （FCS） 
for 24 h before being transferred to SmBM without FCS to synchronize the cell cycle.  VSMCs 
were incubated for 48 h with PDGF-BB （20 ng / ml） and GLP-1, liraglutide, or exendin-4 at 
concentrations indicated, together with 2 µmol / l PKF-275 to prevent the incretin from degrading. 
Cells were exposed to 10 µmol / l 5'-bromo-2'-deoxyuridine （BrdU） for the last 20 h of culture 14）. 
BrdU-positive cells were visualized by immunostaining and counted under a microscope.
Human VSMC migration assay
　Cell migration was measured using modified Boyden chambers （Neuro Probe, Gaithersburg, 
MD, USA）.  Each chamber housed a polycarbonate filter with 8-µm pores that had been 
incubated with 5.3 mg / ml collagen （Centrix, Santa Clara, CA, USA） in phosphate-buffered saline 
（PBS） for 30 min before the migration assay 14）.  Human aortic VSMCs （3-5×103 cells / 100 µl 
per well） were plated on the top chamber of a Transwell plate （Transwell-Costar, Cambridge, 
MA, USA） and 20 ng / ml PDGF-BB was dispensed into the lower chamber.  The cells were 
then incubated for 20 h with the indicated concentration of GLP-1 together with the vildagliptin 
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analog PKF-275 （2 µmol / l）.  After incubation, the non-migrating cells were removed from the 
upper face of the Transwell membrane with a cotton swab and the migrating cells were fixed 
and stained with crystal violet in 3.7％ paraformaldehyde.  Migration was quantified by counting 
the number of positively stained cells.
Animal experiments
　Animal experiments were performed in accordance with National Institutes of Health （NIH） 
guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee of Showa University.  Sixteen male apoE-/- mice were 
purchased from Sankyo Labo Service （Tokyo, Japan） at 8 weeks of age and were maintained 
on a normal diet until they reached 17 weeks of age.  At this time, apoE-/- mice were divided 
into two groups and infused with either GLP-1 （2.2 nmol / kg per day） or saline （vehicle） for 
4 weeks via osmotic mini-pumps （Alzet Model 1007D ; Durect, Cupertino, CA, USA）13, 15）.  The 
osmotic mini-pumps had been implanted subcutaneously on the back of the mice.  Mice were 
simultaneously fed an atherogenic diet containing 30％ fat, 20％ sucrose, 8％ NaCl, and 0.15％ 
cholesterol （Oriental Yeast, Tokyo, Japan） for 4 weeks 16）.  Then, after 4 weeks infusion, systolic 
blood pressure （SBP） was measured using indirect tail-cuff equipment （MK-2000 ; Muromachi 
Kikai, Tokyo）.  Blood samples were collected from the inferior vena cava after mice had been 
fasted for 12 h.  All surgery was performed in mice anesthetized with diethyl ether.  Plasma 
concentrations of glucose were measured by enzymatic methods using an autoanalyzer （Hitachi 
7020 ; Hitachi, Tokyo, Japan）.
Assessment of atherosclerotic lesions
　After the 4-week infusion period, the 21-week-old apoE-/- mice were anesthetized with diethyl 
ether, drained of blood via the descending vena cava, and subjected to whole-body perfusion 
with PBS via a left ventricular cannula 13, 16-19）.  The whole aorta was fixed by perfusion with 
PBS containing 4％ paraformaldehyde, excised from the root to the abdominal area, and 
carefully stripped of connective and adipose tissues.  Next, cross-sections of the aortic root 
were stained with anti-human SM2 antibody（Yamasa, Tokyo, Japan）and anti-SMemb antibody
（Yamasa）to assess the contractive and proliferative VSMC phenotypes, respectively.  VSMC-
positive areas are expressed as a percentage of the area of atheromatous plaques.
Statistical analysis
　Data are expressed as the mean ± SEM.  Parameters were compared between the two groups 
by unpaired Student’s t-test.  The significance of differences was determined using GraphPad 
Prism 5（GraphPad Software Inc., San Diego, CA, USA）.  Differences were considered significant 
at P＜ 0.05.
Results
　The body weight of saline- and GLP-1-infused apoE-/- mice was comparable（30 ± 1 vs 29 ±
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1 g, respectively ; P＝ 0.56）, as was systolic blood pressure（99 ± 3 vs 102 ± 3 mmHg, respectively ;  
P＝ 0.61）, and serum glucose（131 ± 7 vs 141 ± 10 mg / dl, respectively ; P＝ 0.48）.
Effects of GLP-1 on proliferative VSMCs in atherosclerotic lesions in apoE-/- mice
　Similar to results reported previously 13）, apoE-/- mice infused with saline vehicle in the present 
study exhibited marked atherosclerotic lesions in the proximal portion of the aorta at 21 weeks 
of age, whereas 4-week infusion of GLP-1 significantly suppressed the size of the atherosclerotic 
lesions with infiltrating monocytes / macrophages in the aortic root.  Staining of cross-sections of 
the aortic root with anti-SM2 antibody or anti-SMemb antibody（Fig. 1A）revealed that GLP-
1 infusion significantly decreased SMemb（i.e. the proliferative VSMC phenotype）by 33.9％ 
compared with staining in the saline-treated group（P＜0.01; Fig. 1A, C）.  However, GLP-1 
infusion had no significant effect on SM2 staining（i.e. the contractile phenotype）within aortic 
atherosclerotic lesions in apoE-/- mice（Fig. 1A, B）.
Effects of GLP-1 on the proliferation of human VSMCs
　PDGF-BB significantly stimulated the proliferation of human aortic VSMCs by three fold
（Fig. 2A, B）.  Alone, PKF-275, a DPP-4 inhibitor, did not suppress PDGF-BB-induced VSMC 
proliferation.  Incubation of cells with 0.1 and 1 nmol / l GLP-1 significantly suppressed PDGF-
BB-induced VSMC proliferation by 39.1％ and 49.9％, respectively （P＜0.001 for both ; Fig. 
2A, B）.  In another series of experiments, 1 nmol / l GLP-1 significantly suppressed PDGF-BB-
induced VSMC proliferation （P＜0.03 ; Fig. 3A） and this effect was significantly ameliorated 
by the GLP-1R antagonist exendin（9−39） （50 nmol / l ; P＜0.05 ; Fig. 3A）.  The GLP-1R 
Fig. 1.　Suppressive effects of chronic glucagon-like peptide-1 （GLP-1） infusion against the proliferative or contractile 
vascular smooth muscle cell （VSMC） phenotype in aortic atherosclerotic lesions in apolipoprotein E-deficient
（apoE-/-） mice. Sixteen apoE-/- mice were infused with GLP-1 （2.2 nmol / kg per day） or saline （control） 
by osmotic mini-pump for 4 weeks from 17 weeks of age. （A） Cross-sections of the aortic root were 
stained with anti-SM2 antibody or anti-SMemb antibody to identify contractile and proliferative phenotypes, 
respectively. （B, C）Quantitative analysis of areas positive for anti-SM2 antibody（B）and anti-SMemb 
antibody （C） relative to atherosclerotic lesions in percentage terms. Data are the mean ± SEM. ＊P＜0.01 
compared with control.
＊
A
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agonist liraglutide （100 nmol / l） mimicked GLP-1, significantly suppressing PDGF-BB-induced 
VSMC proliferation by 42.7％ （P＜0.03 ; Fig. 3B）, as did the other GLP-1R agonist exendin-4
（100 nmol / l）, which suppressed PDGF-BB-induced VSMC proliferation by 48.6％（P＜0.03 ;  Fig. 
3B）.
Effects of GLP-1 on the migration of human VSMCs
　PDGF-BB significantly stimulated the migration of human aortic VSMCs by 1.7 -fold.  Alone, 
the DPP-4 inhibitor PKF-275 had no significant effect on PDGF-BB-induced VSMC migration. 
Incubation of cells with 1 nmol / L GLP-1 significantly suppressed PDGF-induced VSMC 
migration by 19.3％ （P＜ 0.01 ; Fig. 4A, B）.  Although incubation of cells with 0.1 nmol / l GLP-
1 suppressed PDGF-induced VSMC migration by 18.8％, the difference failed to reach statistical 
significance（Fig. 4A, B）.
Discussion
　The results of the present study suggest that GLP-1 treatments may prevent the progression 
of atherosclerotic lesions by suppressing the proliferation and migration of VSMCs, which are 
characteristic features of atherosclerosis.  The present study is the first to show the suppressive 
effects of GLP-1 and GLP-1R agonists on PDGF-BB-induced proliferation and migration of 
human aortic VSMCs.  The present study also showed that GLP-1 suppressed SMemb-positive 
VSMCs, a proliferative phenotype that acquires macrophage-like phagocytosis 20）.  In previous 
studies we showed that chronic infusion of GLP-1 significantly prevented the infiltration of 
Fig. 2.　Suppressive effects of glucagon-like peptide-1 （GLP-1） on the platelet-derived growth factor （PDGF）- 
BB-induced proliferation of human vascular smooth muscle cells（VSMCs）. Human aortic VSMCs were 
seeded onto six-well plates （3×104 cells / ml per well）, cultured in smooth muscle cell basal medium （SmBM）
supplemented with 5％ fetal calf serum （FCS） for 24 h, and then transferred to SmBM without FCS. VSMCs 
were incubated for 48 h with PDGF-BB （20 ng / ml） and the indicated concentrations of GLP-1, together 
with a vildagliptin analog （2 µmol / l）. Cells were exposed to 10 µmol / l bromodeoxyuridine （BrdU） for the 
last 20 h of culture. （A, B） BrdU-positive cells （arrows in 2A） were visualized by immunostaining （A） and 
counted under a microscope （B）. Data are the mean ± SEM. ＊P＜0.001 compared with column 3.
A B
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Fig. 3.　Effects of a glucagon-like peptide-1 （GLP-1） receptor （GLP-1R） antagonist and agonists on human vascular 
smooth muscle cell （VSMC） proliferation. Human aortic VSMCs were seeded onto six-well plates（3×104 
cells / ml per well）, cultured in smooth muscle cell basal medium （SmBM） supplemented with 5％ fetal 
calf serum（FCS）for 24 h, and then transferred to SmBM without FCS. （A） VSMCs were incubated for 
48 h with platelet-derived growth factor（PDGF）-BB（20 ng / ml）and GLP-1（1 nmol / l）, together with a 
vildagliptin analog（2 µmol / l）, in the presence or absence of 50 nmol / l exendin（9−39）. （B） VSMCs were 
incubated for 48 h with 20 ng / ml PDGF-BB and 100 nmol / l liraglutide or 100 nmol / l exendin-4, together 
with a vildagliptin analog（2 µmol / l）. Cells were exposed to 10 µmol / l bromodeoxyuridine （BrdU） for the 
last 20 h of culture. BrdU-positive cells were visualized by immunostaining and counted under a microscope. 
Data are the mean ± SEM. ＊P＜ 0.03 ; #P＜ 0.05.
Fig. 4.　Suppressive effects of glucagon-like peptide-1 （GLP-1） against the platelet-derived growth factor （PDGF）- 
BB-induced migration of human vascular smooth muscle cells（VSMCs）. Human aortic VSMCs （3−5×
103 cells / 100 µl per well） were plated on the Transwell plates of the top chamber of a Boyden chamber 
assay kit, and PDGF-BB（20 ng / ml）was dispensed into the lower chamber. After 20 h incubation with the 
indicated concentrations of GLP-1 together with a vildagliptin analog （2 µmol / l）, all non-migratory cells were 
removed from the upper face of the Transwell membrane with a cotton swab and the migratory cells were 
fixed and stained with crystal violet in 3.7％ paraformaldehyde （A）. Migration was quantified by counting the 
number of stained cells（B）. Data are the mean ± SEM. ＊P＜ 0.01 compared with column 3.
A
A
B
B
＊
＊
＊
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monocytes / macrophages into the arterial wall, the development of atherosclerotic lesions, 
and oxLDL-induced macrophage foam cell formation in apoE-/- mice 13）.  Suppression of 
the proliferation and migration of VSMCs by GLP-1 may explain, in part, prevention of the 
atherogenic process in these mice.  The anti-atherogenic effects exhibited by GLP-1 and GLP-1R 
agonists in vitro in human VSMCs and in vivo in apoE-/- mice may have important implications 
for future research.  Gaspari et al have shown that liraglutide infusion into apoE-/- mice inhibits 
both endothelial dysfunction and expression of vascular adhesion molecule 21）.  Goto et al 
reported that exendin-4 suppresses murine VSMC proliferation and reduces intimal thickening 
after vascular injury 9）.  These findings are similar to those of the present study and suggest that 
incretin-based therapy may be effective for the prevention of atherosclerotic vascular diseases.
　DPP-4 acts on human VSMCs and monocytes / macrophages, and is present in human serum 
contained in culture medium 22, 23）.  In preliminary studies, GLP-1 had far weaker suppressive 
effects against human macrophage foam cell formation and human VSMC migration and 
proliferation when the culture media were prepared without DPP-4 inhibitor.  Therefore, in the 
present study, we used DPP-4 inhibitors to prevent degradation of GLP-1 in all ensuing in vitro 
experiments investigating the suppressive effects of this incretin on human vascular cells.
　The concentrations of GLP-1 used in vitro （0.1−1 nmol / l）in studies of human VSMC 
proliferation and migration are higher than concentrations found in vivo in plasma from non-
fasted patients with diabetes（2−40 pmol / l）24, 25）.  It has been reported that GLP-1 administered 
via buccal tablets（119 nmol）or via continuous infusion（2.16 nmol / kg per day for 2 days）
increases plasma GLP-1 concentrations in humans to a peak of 100−120 pmol / l 26, 27）.  Therefore, 
the combined use of DPP-4 inhibitors and GLP-1 could conceivably lead to higher plasma 
concentrations of GLP-1.  In humans infused with liraglutide once daily, plasma concentrations 
have been reported to reach 10 nmol / l liraglutide 28）.  Thus, the concentrations of GLP-1 used in 
the present study do not far exceed the plasma concentrations reached when a GLP-1 analog is 
administered.
　The mechanisms underlying the suppressive effects of incretins on the proliferation and 
migration of VSMCs remain to be elucidated.  Goto et al 9） investigated the molecular 
mechanisms underlying exendin-4-mediated suppression of VSMCs, however their results did 
not enable them to reach any definitive conclusions.  Because GLP-1 has suppressive effects 
on VSMCs, it is likely that these effects are mediated by cAMP generation following activation 
of GLP-1R.  However, Goto et al 9） did not find increased cAMP levels in exendin-4-treated 
VSMCs.  Hattori et al 10） found that activation of GLP-1R induces phosphorylation of AMP-
activated protein kinase （AMPK） independent of adenylate cyclase activity in endothelial cells. 
AMPK activation by the GLP-1 signal transduction pathway may be involved in the inhibition 
of VSMC proliferation.  Further studies are required to elucidate the molecular mechanisms 
underlying the suppression of the proliferation and migration of VSMCs by incretins, and 
whether these mechanisms are dependent or independent of cAMP.
　There are several obstacles in translating the findings of the present study to humans.  First, 
unlike humans, in whom the etiology of atherosclerosis is multifactorial, the atherosclerosis in our 
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animal model is due simply to hypercholesterolemia without any other risk factors.  Furthermore, 
in the present study we started the intervention in young （17-week-old） mice and evaluated 
atherosclerotic lesions 4 weeks later.  Therefore, this study evaluated the effects of intervention at 
a young age on the development of atherosclerosis, which differs from the design of intervention 
studies in humans, in which cardiovascular events or mortality are considered as end-points at 
older ages.
　The Examine SAVOR （Saxagliptin and cardiovascular outcomes in patients with type 2 
diabetes mellitus） study in humans failed to demonstrate a suppressive effect of a DPP-4 
inhibitor on cardiovascular events29）.  Therefore, other evidence is needed to determine whether 
incretin-based treatment will really suppress atherosclerosis in humans.  Based on the findings of 
Examin SAVOR, it is difficult at present to extend our findings to suppression of atherosclerosis 
in humans.  However, if it could be demonstrated that incretin-based treatment suppressed 
atherosclerosis in humans, our results would contribute to an understanding of the mechanisms 
involved and perhaps the development of appropriate treatment.
　In conclusion, the results of the present study indicate that GLP-1 and GLP-1R agonists 
suppress VSMC migration and proliferation, and are thereby capable of preventing the 
progression of atherosclerotic lesions.  GLP-1-related treatments are expected to emerge as a new 
line of therapy against atherosclerotic vascular diseases in diabetics.
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